Talquetamab monotherapy [TALQ1]

For treating relapsed or refractory multiple myeloma after 3 or more treatments where the following criteria have been met:

1. This application is being made by, and drugs prescribed by, a consultant or senior resident doctor specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient is an adult with proven relapsed or refractory multiple myeloma.

Note

Note: patients with amyloidosis or POEMS syndrome are not eligible for talquetamab.

3. The patient has had 3 or more lines of treatment, according to the definition below, which must include:

• an immunomodulatory drug
• a proteasome inhibitor and
• an anti-CD38 antibody The numbering of a line of treatment is in accordance with the International Myeloma Workshop Consensus recommendations for the uniform reporting of clinical trials (http://doi.org/10.1182/blood-2010-10-299487). A line of therapy is defined as one or more cycles of a planned treatment program. This may consist of one or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner (ie induction chemotherapy/chemotherapies when followed by stem cell transplantation is considered to be 1 line of therapy). A new line of therapy starts when a planned course of therapy is modified to include other treatment agents (alone or in combination) as a result of disease progression, relapse or toxicity, the exception to this being the need to attain a sufficient response for stem cell transplantation to proceed. A new line of therapy also starts when a planned period of observation off therapy is interrupted by a need for additional treatment for the disease. Please record at which line of therapy talquetamab is being given:
• as 4th line of therapy
• as 5th line of therapy
• as 6th or subsequent line of therapy

4. This patient has been previously treated with at least one immunomodulatory agent. Please confirm how many immunomodulatory agents have been used to treat this patient’s myeloma:

• 1 immunomodulatory agent
• 2 or more different immunomodulatory agents

5. This patient has been previously treated with at least one proteasome inhibitor. Please confirm how many different proteasome inhibitors have been used to treat this patient’s myeloma:

• 1 proteasome inhibitor
• 2 or more different proteasome inhibitors

6. This patient has been previously treated with at least one anti-CD38 antibody. Please confirm how many anti-CD38 antibodies have been used to treat this patient’s myeloma:

• 1 anti-CD38 antibody
• 2 or more different anti-CD38 antibodies

7. The patient has either previously received a pomalidomide-containing regimen or not.

• no, the patient has not been treated with a pomalidomide containing regimen
• yes, the patient has been treated with a pomalidomide-containing regimen

8. The patient has either previously received a bispecific antibody or not.

• the patient has been treated with teclistamab
• the patient has been treated with elranatamab
• the patient has been treated with belantamab
• no treatment with a bispecific antibody has been given

9. Myeloma has progressed on the last treatment.
10. The patient has an ECOG performance status of 0, 1 or 2. Please record below the ECOG performance status:

• PS 0
• PS 1
• PS 2

11. The patient will be treated with talquetamab until loss of clinical benefit or the occurrence of excessive toxicity or the withdrawal of patient consent, whichever is the sooner.

Note

Note: once talquetamab is electively stopped (ie for reasons other than temporary toxicity), it cannot be re-started.

12. When a treatment break of more than 6 weeks beyond the expected weekly or 2-weekly cycle length (as appropriate) is needed, a treatment break approval form will be completed to restart treatment.
13. Talquetamab will be used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 17 November 2025

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.378 of the CDF list, downloaded from NHS England’s website on 18 November 2025 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.